Enrichment of superoxide dismutase 2 in glioblastoma confers to acquisition of temozolomide resistance that is associated with tumor-initiating cell subsets

Intratumor subsets with tumor-initiating features in glioblastoma are likely to survive treatment. Our goal is to identify the key factor in the process by which cells develop temozolomide (TMZ) resistance.

Source: Journal of Biomedical Science - October 19, 2019 Category: Biomedical Science Authors: Chia-Hung Chien, Jian-Ying Chuang, Shun-Tai Yang, Wen-Bin Yang, Pin-Yuan Chen, Tsung-I Hsu, Chih-Yuan Huang, Wei-Lun Lo, Ka-Yen Yang, Ming-Sheng Liu, Jui-Mei Chu, Pei-Hsuan Chung, Jr-Jiun Liu, Shao-Wen Chou, Shang-Hung Chen and Kwang-Yu Chang Tags: Research Source Type: research